Chinese meta-analysis: bisphosphonates lower risk for endometrial cancer

  • Zhang XS & al.
  • Gynecol Oncol
  • 27 Jun 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Bisphosphonate use was associated with significant reduction in the risk for endometrial cancer vs no use, but not ovarian cancer.
  • Bisphosphonate use for >1 year reduces the risk by 43%, and by 47% in postmenopausal women.

Why this matters

  • Published data on the association between bisphosphonate use and ovarian/endometrial cancer are inconsistent.

Study design

  • Meta-analysis of 7 studies identified after a search on MEDLINE, EMBASE, and Web of Science databases.
  • 6471 women with endometrial cancer from 7 studies (213,920 participants) and 6783 women with ovarian cancer from 4 studies (105,507 participants) were included.
  • Funding: None.

Key results

  • Any use of bisphosphonates was associated with 27% reduction in the risk for endometrial cancer (relative risk [RR], 0.73; P=.012) vs no use.
  • In postmenopausal women, bisphosphonate use was associated with 47% lower risk for endometrial cancer (RR, 0.53; P=.012) vs no bisphosphonates.
  • Bisphosphonate use for >1 year was associated with significant reduction in endometrial cancer (RR, 0.57; P=.024).
  • Use of bisphosphonates was not associated with risk for ovarian cancer (RR, 0.81; P=.227).

Limitations

  • Moderate to high heterogeneity.
  • Data on bisphosphonate and tumor type were lacking.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit